Background
Intermedin/Adrenomedullin 2 (IMD/AM2) is a novel peptide related to the calcitonin gene-related peptide family. It is a vascular regulatory factor of homeostasis and a vital endogenous protective factor against vascular diseases. This in vitro study was designed to the effect of IMD/AM2 on platelet aggregation with several platelet aggregation agents in the healthy volunteers.
Methods
The study was carried out on 7 healthy volunteers. Blood samples were centrifuged to prepare platelet-rich plasma and platelet-poor plasma. The platelet-rich plasma was diluted with the platelet poor plasma to yield test platelet-rich plasma with a final platelet count of 300,000±25,000 platelets L−9. Three concentration of IMD/AM2 solutions were prepared that would result in 10-8, 10-7, and 10-6 M. Each concentration of IMD/AM2 was incubated with platelet-rich plasma at 37 C during one hour. Platelet aggregation studies were carried out in platelet-rich plasma using 3μg ml−1 collagen, 10μM ADP, and 10μM epinephrine. In addition, spontaneous aggregation was performed for each concentration of IMD/AM2 incubated platelet-rich plasma.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
